<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039390</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02467</org_study_id>
    <secondary_id>UCHSC-01479</secondary_id>
    <secondary_id>U01CA099176</secondary_id>
    <secondary_id>CDR0000069379</secondary_id>
    <nct_id>NCT00039390</nct_id>
  </id_info>
  <brief_title>Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of gefitinib and capecitabine&#xD;
      in treating patients with advanced solid tumors. Biological therapies such as gefitinib may&#xD;
      interfere with the growth of tumor cells and slow the growth of solid tumors. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining gefitinib and capecitabine may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of gefitinib and capecitabine in patients with&#xD;
      advanced solid tumors.&#xD;
&#xD;
      II. Determine the dose-limiting toxic effects of this regimen in these patients.&#xD;
&#xD;
      III. Determine the pharmacologic profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of gefitinib and capecitabine.&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on&#xD;
      days 8-21. Treatment repeats every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and&#xD;
      capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 11-41 patients will be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) defined as the those below that results in dose-limiting toxicity (DLT) in &gt;= 2 of 6 new patients, as assessed by CTCAE version 3.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DTL defined as any grade 3 or greater non-hematological toxicity, and grade 3 or greater skin rash, grade 4 thrombocytopenia and/or neutropenia as assessed by CTCAE version 3.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacological profile</measure>
    <time_frame>At baseline, at 30 minutes, at 1, 2, 3, and 4 hours of days 8, 14, and 21 (course 1)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (capecitabine, gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given orally (PO)</description>
    <arm_group_label>Treatment (capecitabine, gefitinib)</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (capecitabine, gefitinib)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (capecitabine, gefitinib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (capecitabine, gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor that is refractory to standard therapy&#xD;
             or for which no standard therapy exists&#xD;
&#xD;
          -  No uncontrolled brain metastases, including symptomatic lesions or lesions requiring&#xD;
             treatment (e.g., glucocorticoids and/or anticonvulsants)&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No active infections&#xD;
&#xD;
          -  No other serious concurrent systemic disorders that would preclude study participation&#xD;
&#xD;
          -  No other malignancy&#xD;
&#xD;
          -  No prior hypersensitivity to sulfonamide-based drugs, nonsteroidal anti-inflammatory&#xD;
             drugs, or fluorouracil&#xD;
&#xD;
          -  No documented dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent experimental medications&#xD;
&#xD;
          -  No concurrent drugs known to induce cytochrome P450 3A4 (e.g., rifampin, phenytoin,&#xD;
             carbamazepine, or barbiturates)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Basche</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

